 This study found that the anti-CGRP monoclonal antibody, Fermanizumab reduced facial sensitivity to noxious mechanical and thermal stimuli in female rats. This suggests that anti-CGRP antibodies may be effective in reducing both headaches and cranial sensitivity in migraine patients. This article was authored by Nicola Benedicter, Carl Messlinger, Birgit Vogler, and others.